Deutsche Bank set a $9.00 price objective on TherapeuticsMD (NASDAQ:TXMD) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued research reports about the company. Oppenheimer reaffirmed an outperform rating and issued a $10.00 price objective on shares of TherapeuticsMD in a research note on Thursday, August 31st. BidaskClub upgraded TherapeuticsMD from a strong sell rating to a sell rating in a report on Tuesday, December 12th. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday, September 8th. They set an equal weight rating and a $6.00 price objective for the company. Noble Financial restated a buy rating on shares of TherapeuticsMD in a report on Thursday, November 30th. Finally, Cantor Fitzgerald restated a buy rating and set a $31.00 price objective on shares of TherapeuticsMD in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $14.88.

Shares of TherapeuticsMD (TXMD) opened at $5.84 on Wednesday. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30. The stock has a market capitalization of $1,240.00, a P/E ratio of -14.97 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the previous year, the company posted ($0.13) EPS. The company’s revenue was down 19.7% compared to the same quarter last year. equities analysts predict that TherapeuticsMD will post -0.37 earnings per share for the current year.

In other news, Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 23.92% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. raised its position in shares of TherapeuticsMD by 10.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after acquiring an additional 50,000 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after acquiring an additional 67,855 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of TherapeuticsMD by 26.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after acquiring an additional 30,030 shares in the last quarter. Swiss National Bank raised its position in shares of TherapeuticsMD by 12.3% in the 3rd quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after acquiring an additional 31,800 shares in the last quarter. Finally, Stifel Financial Corp raised its position in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after acquiring an additional 1,622,668 shares in the last quarter. 73.69% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://theolympiareport.com/2017/12/24/therapeuticsmd-txmd-pt-set-at-9-00-by-deutsche-bank.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.